Brief: Vaxxinity Announces UB-312 Successfully Met Primary Objectives Of Phase 1 Clinical Trial In Parkinson’s Disease

Vaxxinity

22/06/2023 13:07

June 22 (Reuters) - Vaxxinity Inc  VAXX.O :
    * VAXXINITY ANNOUNCES UB-312 SUCCESSFULLY MET PRIMARY
OBJECTIVES
OF PHASE 1 CLINICAL TRIAL IN PARKINSON’S DISEASE
    * VAXXINITY INC - UB-312 WAS IMMUNOGENIC IN PATIENTS WITH
EARLY
PARKINSON'S DISEASE
    * VAXXINITY INC - UB-312 WAS GENERALLY SAFE AND
WELL-TOLERATED
    * VAXXINITY- RESULTS ARE CONSISTENT WITH CONCLUSIONS FROM
PHASE 1
PART A,PRECLINICAL STUDIES, SUPPORT ADVANCEMENT OF UB-312 INTO
FURTHER CLINICAL DEV
    * VAXXINITY INC - TWO PATIENTS EXPERIENCED SERIOUS ADVERSE
EVENTS
    * VAXXINITY INC - ONLY ONE EVENT WAS DEEMED POSSIBLY RELATED
TO
TRIAL, AND ALL SAES WERE RESOLVED

Source text for Eikon:  ID:nGNX4b9YH7 
Further company coverage:  VAXX.O 

 (Reuters.Briefs@thomsonreuters.com)